BioTuesdays

Category - Developments

Titan Pharmaceuticals Logo
Developments

FDA panel to review NDA for Probuphine

The FDA’s Psychopharmacologic Drugs Advisory Committee has scheduled a meeting on Jan. 12 to review the NDA for Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine for the maintenance treatment of opioid addiction. The FDA...

December 9, 2015
ciclofilin pharma
Developments

Ciclofilin Pharma forms liver disease SAB

Closely-held Ciclofilin Pharmaceuticals has assembled a world-class team of scientists and clinicians for its scientific advisory board (SAB) to guide the company through its drug development program for its lead drug...

December 3, 2015
Kitov Pharma
Developments

Kitov Pharma prices U.S. IPO

Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) has priced an initial public offering of 3,158,900 American Depository Shares (ADS) and warrants to purchase up to 3,158,900 ADS for gross proceeds expected to be...

November 24, 2015
Can-Fite
Developments

Can-Fite expands development of CF102 into NASH

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, which is currently in Phase 2 trials for hepatocellular carcinoma (HCC), the most common form of liver cancer, will be expanded into the treatment...

November 23, 2015
Viking Therapeutics Logo
Developments

Viking, Kennedy Krieger to collaborate in X-ALD

Viking Therapeutics (NASDAQ:VKTX) and the Kennedy Krieger Institute announced a sponsored research collaboration focused on evaluating Viking’s thyroid beta agonists for the treatment of X-linked adrenoleukodystrophy (X...

November 23, 2015